Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,633

Document Document Title
WO/2018/226339A1
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases in pediatric subjects, and related methods.  
WO/2018/223243A1
There are provided compositions and methods for prevention or treatment of Streptococcus pneumoniae (SP)-associated diseases. More specifically, there are provided recombinant lipidated fusion proteins comprising pneumococcal surface ant...  
WO/2018/225662A1
Natural immunity is induced in a subject animal by administering to the subject animal a fused protein comprising at least two toxin B subunits selected from among the B subunit of Shiga toxin 2e (Stx2eB), the B subunit of a heat-labile ...  
WO/2018/223600A1
Provided in the present invention are an OCTS-CAR dual targeting chimeric antigen receptor based on OCTS technology, an encoding gene, an OCTS-CAR-T recombinant expression vector and a construction method and the use thereof. The OCTS-CA...  
WO/2018/225781A1
The purpose of the present invention is to provide a monoclonal antibody that functions even in a state of intracellular reduction. The problem can be solved by a monoclonal antibody containing a heavy-chain variable region domain compri...  
WO/2018/223764A1
Disclosed are a human sDR5-Fc recombinant fusion protein and the use of same in the preparation of a drug for treating reproductive system inflammation. In particular, a fusion protein of the soluble fragment of the human DR5 and the Fc ...  
WO/2018/225732A1
[Problem] To provide CAR T cells that can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used. [Solution] The problem is solved by CAR T cells for cancer therapy provided with an antibody that recogni...  
WO/2018/226757A1
Materials and methods for identifying modulators of protein function (e.g., enzyme activity), including modulators that target particular substrates for enzymes, are provided herein.  
WO/2018/223601A1
Provided in the present invention are an anti-PSCA and anti-PDL1 dual targeting chimeric antigen receptor based on the OCTS-CAR, an encoding gene, an OCTS-CAR-T recombinant expression vector and a construction method and use thereof. The...  
WO/2018/219301A1
Disclosed is a tumor necrosis factor-related apoptosis-inducing ligand variant, which is a fusion protein of a tumor necrosis factor-related apoptosis-inducing ligand and ZPDGFRβ. ZPDGFRβ is connected to the N-terminus or C-terminus of...  
WO/2018/220386A1
The present invention relates to macromolecular complexes comprising micron-scale networks which include binding motifs thereon which allow the covalent bonding of the micron-scale networks to particles which provide nanoscale display su...  
WO/2018/222880A1
Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a ...  
WO/2018/218206A1
Provided herein are fusion proteins useful in a bipartite cytosine base editor system comprising: (i) a first fusion protein comprising a non-R-loop-forming programmable DNA binding domain, preferably a transcription-activator-like effec...  
WO/2018/215391A1
The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt...  
WO/2018/217945A1
Multi-specific binding proteins that bind NKG2D receptor, CD16, and 5T4, a tumor-associated antigen selected from 5T4, GPNMB, FR-alpha, PAPP-A, and GPC3 are described, as well as pharmaceutical compositions and therapeutic methods useful...  
WO/2018/215049A1
The invention comprises a process for the preparation of therapeutically valuable GalNAc cluster oligonucleotide conjugates. The process comprises the coupling of an alkali metal salt, earth alkali metal salt or a tetraalkylammonium salt...  
WO/2018/213934A1
The present disclosure relates to bioactive self-assembling peptides, nanofibers and hydrogels for activating human mast cells. The peptides, nanofibers and hydrogels comprise a self-assembling peptide that mediates self-assembly linked ...  
WO/2018/214757A1
Provided is a recombinant fusion protein. The fusion protein is formed by means of the fusion of a D2 structural domain of an Slit2 protein and an HSA protein, and a 386th amino acid of an Slit2 protein molecule is serine.  
WO/2018/212322A1
The present invention pertains to a method of evaluating the trimer formation capability of type IV collagen, a method of screening for a compound that promotes the trimer formation capability of type IV collagen, and a kit for use with ...  
WO/2018/213747A1
Disclosed are bispecific molecules that comprise a 4-1BB agonist moiety connected to a dendritic cell binding moiety and methods for using such bispecific molecules to treat 4-1BB-related disorders such as cancer. Also disclosed are bisp...  
WO/2018/213467A1
This document provides methods and materials for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-cha...  
WO/2018/213335A1
The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N...  
WO/2018/213351A1
The present disclosure provides RNA-guided endonucleases, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided endonuclease of the present di...  
WO/2018/208124A2
The present invention relates to a compound having a structure in which isotretinoin is linked to a peptide via a covalent bond and an antibiotic, anti-inflammatory, or anti-oxidative pharmaceutical or cosmetic composition comprising the...  
WO/2018/208837A1
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecu...  
WO/2018/205344A1
The present invention belongs to the field of biotechnology, and provides a CEA.CAR-T, a preparation method therefor and use thereof. The present invention firstly provides a chimeric antigen receptor targeting a carcinoembryonic antigen...  
WO/2018/207906A1
The present invention relates to: a protein-peptide fusion body in which a peptide having a function to be adsorbed onto the surface of a substrate is provided on the N-terminal side or the C-terminal side of a protein capable of recogni...  
WO/2018/205985A1
Provided are a fusion protein containing a TGF-β receptor and medicinal uses thereof. Also provided are a dual-functional fusion protein comprising a targeted part of a PD-L1 antibody and a TGF-βRII extracellular region, a pharmaceutic...  
WO/2018/201794A1
Provided is a chimeric antigen receptor (CAR) against human CD19 antigen, consisting of a single-chain antibody (scFv) recognizing human CD19 antigen, a hinge region, a transmembrane region, and an intracellular signaling domain connecte...  
WO/2018/204374A1
The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.  
WO/2018/200586A1
The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.  
WO/2018/200422A1
The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an i...  
WO/2018/196831A1
Disclosed in the present invention are a short peptide, a fluorescence probe and a preparation method thereof. The short peptide comprises a peptide fragment with a load function and a peptide fragment with a recognition function; the pe...  
WO/2018/200585A1
The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a secretory secondary effector (SSE) construct. The caTCR comprises an antigen-binding module that...  
WO/2018/199337A1
The present invention provides a technique that enables modification of a soluble protein, particularly regioselective modification of a soluble protein. More specifically, the present invention provides a compound having a substance tha...  
WO/2018/200582A1
The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling m...  
WO/2018/200583A1
The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that ...  
WO/2018/199777A1
The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting c...  
WO/2018/193033A1
The present invention provides a chromatographic separation method for improving the quality of albumin fusion protein solutions by removing impurities from the albumin fusion protein solution. This invention provides albumin fusion prot...  
WO/2018/195427A2
The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen rece...  
WO/2018/195388A1
Provided are various embodiments relating to IL13R/IL4R contiguous polypeptides derived from companion animal species and that bind to IL13 and/or IL4. Such contiguous polypeptides can be used in methods to treat IL13 and/or IL4-induced ...  
WO/2018/195338A1
Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressi...  
WO/2018/195527A1
The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease ...  
WO/2018/194944A4
A method for diagnosis or aiding in the diagnosis of Sjogren's Syndrome (SS). The diagnosis method requires testing a sample obtained or derived from a subject for an amount of Taxilin alpha, wherein determining an amount of Taxilin alph...  
WO/2018/194944A1
A method for diagnosis or aiding in the diagnosis of Sjogren's Syndrome (SS). The diagnosis method requires testing a sample obtained or derived from a subject for an amount of Taxilin alpha, wherein determining an amount of Taxilin alph...  
WO/2018/190357A1
A purpose of the present invention is to provide a highly sensitive and less expensive lectin-immobilized base material (for example, a lectin plate), said lectin-immobilized base material having stable qualities and being able to be suf...  
WO/2018/191715A3
Disclosed herein are novel polypeptides having nuclease activity. The Mmc3 polypeptides function as Class 2 Type V effectors, and catalyze double stranded breaks in nucleic acid strands. The polypeptides are useful, for example, for gene...  
WO/2018/191557A1
Compositions and methods for treating, mitigating, or preventing a Toll-like receptor (4) (TLR4)-mediated infection or disease in a host cell or a subject include administration of a resistin protein composition selected from full length...  
WO/2018/191490A1
The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Meth...  
WO/2018/190348A1
The present invention pertains to a set of two polypeptides to be used in light-dependent gene recombination wherein an N-terminal fragment and a C-terminal fragment of Cre protein having the amino acid sequence of SEQ ID NO: 1 bind resp...  

Matches 1 - 50 out of 22,633